araag2/HINT huggingface dataset:
Clinical trial NCT00462358 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: arry-520, ksp(eg5) inhibitor; intravenous, filgrastim, granulocyte-colony stimulating factor (g-csf); subcutaneous
SMILES: CON(C)C(=O)N1N=C(S[C@@]1(CCCN)C1=CC=CC=C1)C1=CC(F)=CC=C1F
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histological or cytological evidence of malignancy.

          -  Advanced solid tumors that have recurred or progressed following standard
             therapy(ies).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

          -  Adequate hematology counts and serum chemistry values.

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Treatment with an investigational product or device, or anti-neoplastic therapy (with
             the exclusion of hormone therapy where the therapy will continue at a standard dose
             throughout the study) within 28 days prior to the first dose of study drug.

          -  Major surgery within 28 days prior to the first dose of study drug.

          -  Radiotherapy (RT) within 28 days prior to the first dose of study drug (except if
             local RT to <5% of the bone marrow).

          -  Known positive serology for the human immunodeficiency virus (HIV), hepatitis C,
             and/or active hepatitis B.

          -  Additional criteria exist.
Clinical trial NCT01055652 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Already on voglibose treatment with a steady dosage for at least 8 weeks

          -  Provision of informed consent prior to any study specific procedures

          -  Diagnosed with type 2 diabetes

        Exclusion Criteria:

          -  Having clinically relevant medical history or concurrent disease such as
             cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological
             disease.

          -  The investigator(s)judged that the Subject should not participate in the study
             according to screening test or medical history.
Clinical trial NCT00363350 (phase 1/phase 2, status: completed)
Conditions: sjogren's syndrome
ICD codes: M35.00, M35.01, M35.03, M35.0B, M35.02, M35.05, M35.08
Drugs: rituximab (anti-cd20)
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Stimulated whole saliva secretion ≥ 0,15 ml/min

          -  Male or female > 18 years

          -  Primary SS according to the revised European - U.S. criteria(22)

          -  Positive autoantibodies (IgM-Rf > 10 and SS-A and/or SS-B)

          -  Parotid gland biopsy (paraffine material and fresh frozen tissue) with characteristic
             features of SS performed at time of inclusion (no longer than 12 months ago)

          -  Use of reliable method of contraception during the study

          -  Written informed consent

        Exclusion Criteria:

          -  The presence of any other connective tissue disease

          -  Preceding treatment with anti-TNF or other monoclonal antibodies

          -  Use of prednisone, hydroxychloroquine less than 1 month ago

          -  Use of MTX, cyclophosphamide, cyclosporin, azathioprine and other DMARDS less than 0,5
             year ago

          -  Serum creatine > 2.8 mg/dl (250 micromol/l)

          -  ASAT or ALAT outside 1.5 x upper normal range of the laboratory

          -  Hb < 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females

          -  Neutrophil granulocytes less than 0.5 x 109/l

          -  Platelet count less then 50 x 109/l

          -  Positive pregnancy test or breast-feeding

          -  History of alcohol or drug abuse

          -  Serious infections

          -  Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions,
             chronic or latent infectious diseases or immune deficiency which places the patient at
             an unacceptable risk for participation in the study

          -  History of any malignancy with the exception of completely resected basal cell
             carcinoma of the skin
Clinical trial NCT00659399 (phase 1, status: withdrawn)
Conditions: ovarian carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: fondaparinux
SMILES: CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18 years of age and ≤75 years of age

          -  Biopsy-proven ovarian, tubal or primary peritoneal epithelial adenocarcinomas;

          -  Performance status 0,1 (ECOG) ( table 2)

          -  Patients at high risk of clinical relapse: first remission stage III/IV who were
             suboptimally debulked (residual disease >1 cm)

          -  Patients of any stage who have recurred and are in second chemotherapy induced
             remission. Clinical remission defined as:

               -  absence of symptoms that may be related to disease

               -  imaging without abnormalities greater then or equal to 1 cm suspicious for
                  disease (no ascites)

               -  CA 125 obtained x 1 and <35 units/ml.

          -  Adequate end organ function, defined as the following:

               -  Total bilirubin < 1.5 x ULN

               -  SGOT and SGPT < 2.5 x UNL

               -  Creatinine < 1.5 x ULN

               -  ANC > 1.5 x 109/L

               -  Platelets > 100 x 109/L

               -  Weight ≥ 50 kg

        Exclusion Criteria:

          -  Patients with performance status ECOG =2,3,4

          -  Patients who are on warfarin or prior therapeutic anticoagulation

          -  Patient has another primary malignancy that has required active intervention within 5
             years, with the exception of basal cell skin cancer or a cervical carcinoma in situ.

          -  Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,
             chronic renal disease, or active uncontrolled infection).

          -  Patient who had a major surgery within 2 weeks prior to study entry

          -  Patients with the following lab abnormalities:

               -  WBC <3000

               -  absolute neutrophil count < 1,500

               -  hemoglobin <10 g/dL

               -  platelet < 100,000

               -  creatinine clearance <30 cc/min

               -  serum ALT, AST, or total bilirubin >1.5X the upper limit of normal

          -  Patients with known bleeding disorder
Clinical trial NCT00516672 (phase 1, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: pazopanib, lapatinib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Eligibility criteria:

        Inclusion criteria:

          -  Signed informed consent.

          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor.

          -  Women and men with potential to have children must be willing to practice acceptable
             methods of birth control during the study.

          -  ECOG performance status of 0 or 1.

          -  Adequate bone marrow reserve and hepato-renal function.

          -  Able to swallow and retain oral medication.

          -  For combo part, left ventricular ejection fraction within normal range or above 50%.

        Exclusion criteria:

          -  Prior treatment with pazopanib, and with lapatinib for combo part.

          -  Clinically significant gastrointestinal abnormalities.

          -  Sevier diseases or conditions other than cancer.

          -  Poorly controlled hypertension.

          -  Use of warfarin for therapeutic anticoagulation.

          -  Use of other anti-angiogenesis agents, and other ErbB inhibitors for combo part.

          -  Unresolved and/or unstable toxicities

          -  Pregnant or lactating females
Clinical trial NCT00330252 (phase 1, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: rituximab, alemtuzumab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be diagnosed with B-CLL / SLL (B-chronic lymphocytic leukemia / small
             lymphocytic lymphoma) based on the standard histologic and immunophenotypic criteria
             described in the WHO classification of lymphoid malignancies, including
             immunophenotypic confirmation that the tumor cells co-express B cell antigens CD19 /
             20 and CD5. Mantle cell lymphoma should be excluded based on positive staining of the
             tumor cells for CD23, or the absence of staining of the tumor cells for cyclin D1 or
             the absence of t(11;14).

          -  The above diagnosis must be confirmed at Brigham & Women's Hospital or Dana-Farber
             Cancer Institute.

          -  Subjects must have relapsed after at least one prior fludarabine-containing regimen
             and require treatment based on NCI-WG criteria (Appendix A).

          -  Subjects must have measurable disease (lymphocytosis > 5,000 / ml, or palpable
             lymphadenopathy or CT measurable lymphadenopathy > 1.5 cm, or bone marrow involvement
             >30%).

          -  Men and women of reproductive potential must agree to use an acceptable method of
             birth control during treatment and for six months after completion of treatment.

          -  Age >= 18

          -  WHO Performance status <= 2

          -  Subject has provided written informed consent.

          -  Expected survival > 3 months

        Exclusion Criteria:

          -  History of HIV

          -  Active infection uncontrolled by appropriate antibacterial, antiviral or antifungal
             therapy

          -  Known CNS involvement with CLL

          -  Pregnant (a negative serum pregnancy test should be performed for all women of
             childbearing potential within 7 days of treatment) or currently lactating women

          -  Prior anti-neoplastic therapy within the last three weeks

          -  Patients will NOT be excluded because they have received prior rituximab or
             alemtuzumab
Clinical trial NCT01245088 (phase 1/phase 2, status: withdrawn)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: chondroitin sulfate
SMILES: OC(=O)CC(O)(CC(O)=O)C(O)=O
Reason stopped: 
    sponsor withdrew support after no patients enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          -  1. Colonic or ileocolonic CD diagnosed for at least 3 months. 2. Active CD, defined as
             a Crohn's Disease Activity Index (CDAI; Appendix A) [Best 1976] of greater than 200
             but less than 320 at the time entry into the study.

             3. Age > 18 years. 4. Patients receiving oral or topical 5-aminosalicylates must be on
             a stable dose for four weeks prior to enrollment.

             5. Patients on azathioprine, 6-mercaptopurine, or methotrexate must be on stable doses
             for 14 weeks prior to enrollment.

             6. Patients on corticosteroids must be on stable doses for 2 weeks prior to
             enrollment.

             7. Patients receiving corticosteroid enemas must be on a stable dose for 3 weeks prior
             to enrollment.

             8. Patient on biologic therapy with infliximab, adalimumab, or certolizumab must be on
             stable therapy for 12 weeks prior to enrollment 9. Patient must sign informed consent.

        Exclusion Criteria:

          -  1. Patients with only small bowel CD, fistulizing CD, or gastroduodenal CD without
             colonic involvement.

             2. Patients with known ulcerative colitis. 3. Patients expected to require surgery
             within 30 days for complications of CD. 4. Patients with CD and an intraabdominal
             abscess. 5. Patients requiring continuous antibiotics; antibiotics may be taken up to
             the point of enrollment into the study.

             6. Patients with severe cardiac, pulmonary, or renal disease. 7. Patients with a h/o
             malignancy other than resected basal cell carcinoma of the skin 8. Patients who have
             participated in another clinical research study in the past 8 weeks.

             9. Patients who are pregnant.
Clinical trial NCT00413322 (phase 1, status: completed)
Conditions: tumor
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: belinostat, 5-fluorouracil (5-fu)
SMILES: ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed solid tumors

          -  Advanced colorectal cancer or other adenocarcinomas

          -  Tumor progression after standard chemotherapy, or where none yet approved

          -  At least one unidimensionally measurable lesion

          -  Karnofsky performance >= 70%

          -  Life expectancy of at least 3 months

          -  Age >= 18 years

          -  Signed, written Institutional Review Board (IRB)-approved informed consent

          -  Acceptable liver function:

               -  Bilirubin <= 1.5 x upper limit of normal (ULN)

               -  AST (SGOT) and ALT (SGPT) <= 2.5 x ULN, OR

               -  AST (SGOT) and ALT (SGPT) <= 5 x ULN if liver metastasis

          -  Acceptable renal function:

               -  Serum creatinine within normal limits, OR

               -  Calculated creatinine clearance of >= 60 mL/min/1.73 m2 for certain patients

          -  Acceptable hematologic status:

               -  Absolute neutrophil count (ANC) >= 1500 cells/mm3

               -  Platelet count >= 100,000 (plt/mm3)

               -  Hemoglobin >= 9 g/dL

          -  Urinalysis: No clinically significant abnormalities

          -  Acceptable coagulation status:

               -  Prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits, OR

               -  For patients on anticoagulation therapy, status within therapeutic range

          -  For men and women of child-producing potential, use of effective contraception

          -  Tumors accessible for needle biopsy

        Exclusion Criteria:

          -  Significant cardiovascular disease.

          -  A marked baseline prolongation of QT/QTc interval

          -  Long QT syndrome

          -  Required use of medication on dosing days that may cause torsade de pointes.

          -  Infections requiring intravenous (IV) systemic therapy

          -  Pregnant or nursing women

          -  Treatment with chemotherapy or investigational therapy < 4 weeks (28 days) prior to
             study entry (6 weeks for nitrosoureas, mitomycin C, or Avastin).

          -  Treatment with radiation therapy or surgery either within 2 weeks prior to study
             entry, or not yet recovered if 2-4 weeks prior to study entry.

          -  Unwillingness or inability to comply with protocol procedures.

          -  Known active uncontrolled infection with HIV, hepatitis B, or hepatitis C

          -  Serious nonmalignant disease (e.g. hydronephrosis, liver failure, or other conditions)
             that could compromise protocol objectives in the opinion of the investigator and/or
             the sponsor

          -  Concurrent use of other investigational agent(s)

          -  Serious concurrent medical illness
Clinical trial NCT01284920 (phase 1/phase 2, status: completed)
Conditions: prostate cancer, prostate neoplasms, castration resistant prostate cancer (crpc)
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: mdv3100
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Ongoing androgen deprivation therapy with a GnRH analogue or a bilateral orchiectomy

          -  Progressive disease after prior androgen deprivation therapy (medical or surgical
             castration)

          -  For Expansion Cohort, the patient has no more than two prior chemotherapy regimens
             with at least one regimen containing docetaxel

          -  For Expansion Cohort, the patient must have measurable lesions by RECIST

        Exclusion Criteria:

          -  Metastases in the brain

          -  History of another malignancy except for adenocarcinoma of the prostate within the
             previous 5 years

          -  Use of bicalutamide within 6 weeks prior to study

          -  Radiation therapy within 12 weeks prior to study

          -  Evidence of serious drug hypersensitivity
Clinical trial NCT01105247 (phase 1/phase 2, status: completed)
Conditions: b-cell chronic lymphocytic leukemia, small lymphocytic lymphoma
ICD codes: C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pci-32765
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. FOR TREATMENT-NAIVE GROUP ONLY: Men and women ≥ 65 years of age with confirmed
             diagnosis of CLL/SLL, who require treatment per NCI or International Working Group
             guidelines 15-18

          2. FOR RELAPSED/REFRACTORY GROUP ONLY: Men and women ≥ 18 years of age with a confirmed
             diagnosis of relapsed/refractory CLL/SLL following previous therapy(ie, failed ≥ 2
             previous treatments for CLL/SLL and at least 1 regimen had to have had a purine analog
             [eg, fludarabine] for subjects with CLL)

          3. FOR HIGH-RISK RELAPSED/ REFRACTORYGROUP ONLY: Men and women ≥ 18 years of age with a
             confirmed diagnosis of relapsed/refractory CLL/SLL with suboptimal response to
             chemoimmunotherapy, defined as progression of disease within 24 months of initiation
             of a regimen containing at least a nucleoside analogue or bendamustine in combination
             with a monoclonal antibody or failure to respond to such a regimen. (Note: a minimum
             of 2 cycles of chemoimmunotherapy required for eligibility)

          4. ECOG performance status of ≤ 2

          5. Willing and able to participate in all required evaluations and procedures in this
             study protocol including swallowing capsules without difficulty

        Exclusion Criteria:

          1. Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or other cancer from which the subject has been
             disease free for at least 2 years or which will not limit survival to < 2 years

          2. Any immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 4 weeks
             before first dose of study drug (corticosteroids for disease-related symptoms allowed
             but require 1-week washout before study drug administration)

          3. Central nervous system (CNS) involvement by lymphoma

          4. Major surgery within 4 weeks before first dose of study drug

          5. Concomitant use of medicines known to cause QT prolongation or torsades de pointes

          6. Significant screening electrocardiogram (ECG) abnormalities including left bundle
             branch block, 2nd degree AV block type II, 3rd degree block, bradycardia, and QTc >
             470 msec

          7. Lactating or pregnant
Clinical trial NCT00726180 (phase 1/phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab (herceptin®)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not
             metastasized, or spread to other parts of the body, are eligible for the study.

          -  Participants must have had either a core biopsy or incisional biopsy of their breast
             cancer, but not yet had definitive breast surgery, including lumpectomy or mastectomy.

          -  Participants may not have had a BRCA mutation found on genetic testing.

          -  Participants should have not yet received treatment for their breast cancer,
             including:

               -  chemotherapy,

               -  hormonal therapy,

               -  trastuzumab.
Clinical trial NCT01202643 (phase 1/phase 2, status: terminated)
Conditions: infertility, female
ICD codes: N97.9, N97.0, N97.1, N97.2, N97.8, Z31.81
Drugs: g-csf, saline
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    insufficient recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient's preparing for invitro fertilization and embryo transfer with endometrial
             growth of less than 7 mm, unresponsive to standard treatment

        Exclusion Criteria:

          -  Sickle Cell disease

          -  Renal insufficiency

          -  Upper respiratory infection or Pneumonia

          -  Chronic Neutropenia

          -  Known Past or present malignancy